ESPE Yearbook of Paediatric Endocrinology

Brief summary: This phase 3 double-blind, parallel-group, randomized, placebo-controlled trial over 68 weeks randomised (2:1) 201 adolescents with obesity to receive semaglutide 2.4 mg once weekly or placebo. Both groups also received lifestyle intervention. The primary endpoint was the percentage change in BMI. Treatment with semaglutide produced clinically relevant reductions in BMI and body weight, and improvements in cardiovascular risk factors, which were all significantl...